Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2025-12-11 Capital/Financing Update
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about a Rights Offering, subscription rights, securities description, risk factors, and plan of distribution. This is a regulatory filing related to capital raising but is not a financial report like an Annual Report or Earnings Release. It is not a simple announcement but a full registration statement document. The closest fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is a full registration statement, not just an announcement or summary. Therefore, the classification is CAP with high confidence.
2025-12-11 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a Note Purchase Agreement and the issuance of a promissory note, which are financing activities. The document details terms of the note, interest rates, maturity, and redemption rights, indicating it is an update on capital raising and financing. It is not a full financial report, audit, or earnings release, but rather a specific announcement about financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-11-19 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-17 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 notification filed with the SEC, indicating a late filing of a quarterly report on Form 10-Q for the period ended September 30, 2025. It explains the reason for the delay and provides estimated financial results expected to be reported in the delayed 10-Q. The document does not contain the actual financial statements or substantive financial data but is a notification of late filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is not the report itself but an announcement related to the report's filing status.
2025-11-17 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an equity distribution agreement for the sale of common stock through an at-the-market offering. The text includes information about the offering terms, use of proceeds, risk factors, and plan of distribution. This type of document is a capital raising filing related to financing activities, specifically an equity offering. It is not an annual report, earnings release, or other financial report but a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2025-10-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes information about entry into a material definitive agreement and exhibits such as the amended and restated Certificate of Incorporation. The document is relatively short (3590 characters) and does not contain detailed financial statements or comprehensive financial data. It is a regulatory filing to inform the market of a material event rather than a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2025-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.